BASKING RIDGE, NJ, & HOLMES CHAPEL, UK, May 7, 2024 - DevPro Biopharma and Bespak have announced the completion of early feasibility studies on DP007, a new formulation of albuterol in a pressurized metered dose inhaler (pMDI) which shows comparable performance to Ventolin® HFA but with a significant reduction in greenhouse gas emissions. This breakthrough pMDI is being developed by DevPro Biopharma, a respiratory-focused clinical development accelerator, and Bespak, a leading contract development and manufacturing organization (CDMO) focused on orally inhaled and nasal drug-device combination products. Clinical studies are planned to be initiated by the end of the year to fast-track its development, as the pharmaceutical industry begins to accelerate its transition to climate-friendly respiratory care.
Lexenpharm`s Generic Albuterol Sulfate Receives Approval In US
A high-tech device that can monitor medication use and compliance has been cleared by the FDA for use with AstraZeneca’s Airsupra and Breztri inhalers.
AIRSUPRA® (albuterol/budesonide) now available as the first and only FDA-approved anti-inflammatory rescue option for asthma
Enforcement Report - Week of July 19, 2023
Cipla Issues Voluntary Nationwide Recall of Six Batches of Albuterol Sulfate Inhalation Aerosol, 90 mcg (200 Metered Inhalation) Due to Container Defect
AstraZeneca’s asthma marketing team is pushing the importance of inflammation in asthma. Across two unbranded campaigns targeting patients and healthcare professionals, the drugmaker is communicating a message that is aligned with the effects of its recently approved rescue inhaler Airsupra.
Cipla Issues Voluntary Nationwide Recall of Six Batches of Albuterol Sulfate Inhalation Aerosol Due to Container Defect